Alkermes Plc. Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Alkermes Plc. is a global biopharmaceutical company focused on neuroscience, commercializing products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company completed the separation of its oncology business (Mural Oncology) in November 2023, which is now reported as discontinued operations. In May 2024, the company sold its Athlone, Ireland facility to Novo Nordisk for approximately $97.9 million.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $399.1 million | $617.4 million | $749.5 million | $905.0 million |
| Net Income (Continuing Ops) | $94.7 million | $279.1 million | $133.6 million | $267.1 million |
| Diluted EPS (Continuing Ops) | $0.55 | $1.63 | $0.78 | $1.56 |
| Operating Cash Flow (YTD) | $167.1 million (vs. $194.4 million YTD 2023) | |||
| Cash & Investments (Total) | $962.6 million (as of June 30, 2024) | |||
| Long-Term Debt | $286.5 million (2026 Term Loans) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased significantly compared to the prior year. This was primarily driven by a $256.1 million decrease in manufacturing and royalty revenues for the quarter. The prior year included a one-time receipt of $195.4 million in back royalties and interest from Janssen related to long-acting INVEGA products following a successful arbitration.
- Product Sales Growth: Despite the royalty decline, proprietary product sales increased by $37.8 million (16%) in the quarter. Growth was led by LYBALVI (+52% units) and VIVITROL (+6% units), supported by price increases effective in January 2024.
- Expense Reduction: Operating expenses decreased by $46.9 million in the quarter. Selling, general, and administrative (SG&A) expenses dropped $27.7 million due to disciplined prioritization and a 7% reduction in sales and marketing headcount. R&D expenses decreased $8.6 million.
- Asset Sale: The company recorded a gain of approximately $1.5 million on the sale of the Athlone Facility, which was completed in May 2024.
Outlook, Risks, and Management Commentary
- INVEGA Royalty Sunset: Management expects royalty revenues from INVEGA SUSTENNA to end on August 20, 2024, which will significantly impact revenue in the second half of 2024. Royalties for INVEGA TRINZA and HAFYERA continue through 2030.
- Share Repurchases: In February 2024, the board authorized a $400 million share repurchase program. The company repurchased approximately 3.5 million shares for $84.7 million in the first half of 2024, with $315.3 million remaining authorized.
- Development Pipeline: The company is advancing ALKS 2680 for narcolepsy, with Phase 2 studies ongoing. Phase 2 studies for narcolepsy type 2 are expected to initiate in Q3 2024.
- Legal Risks: The company faces ongoing Paragraph IV litigation regarding generic versions of INVEGA SUSTENNA, INVEGA TRINZA, and VUMERITY. While the company is not a party to the INVEGA litigation (Janssen is the plaintiff), the outcome could affect royalty streams. The company is also defending a product liability case regarding VIVITROL.
- Liquidity: Management believes existing cash, cash equivalents, and investments are sufficient to fund operations and debt service for at least the next 12 months.
Investor Verification Checklist
- INVEGA SUSTENNA Royalty Cessation: Verify the financial impact of the August 20, 2024, expiration of INVEGA SUSTENNA royalties on H2 2024 guidance.
- Generic Competition: Monitor the status of ANDA litigation for INVEGA SUSTENNA, INVEGA TRINZA, and VUMERITY, as generic entry could accelerate revenue declines.
- Share Repurchase Execution: Track the pace of the remaining $315.3 million share repurchase authorization.
- ALKS 2680 Progress: Confirm the initiation and results of the Phase 2 clinical trials for narcolepsy type 2.
- Discontinued Operations: Ensure financial statements are reviewed on a continuing operations basis, as the oncology business (Mural) is now separate.